Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI3 plus panitumumab or bevacizumab as consolidation after chemoradiotherapy in locally advanced rectal cancer
jRCTs031190023Phase 2Recruiting
- Start
- Aug 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab, bevacizumab, irinotecan, fluorouracil and folinic acid in rectal cancer and rectal adenocarcinoma (2 arms). Primary endpoint: Clinical complete response rate. Started Aug 2019; status: recruiting.
02
Drugs
panitumumabbevacizumabirinotecanfluorouracilfolinic acid
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on jRCTs031190023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190023.